Protocol Ledger

NCT06762769 · Phase II · RECRUITING

Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

Interventional Phase II clinical trial protocol NCT06762769 sponsored by University College, London in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-02 Enrollment: 63 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06762769
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)63 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06762769
Protocol FieldVerified Registry Value
NCT IdentifierNCT06762769
Consolidated Lead SponsorUniversity College, London
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment63 participants (ESTIMATED)
Registered Start Date2025-06-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06762769
Hospital Research SiteLocationSite Profile
Churchill HospitalOxford, United KingdomOpen Hospital Dossier ->
University College London HospitalLondon, United KingdomOpen Hospital Dossier ->
King's College Hospital NHS Foundation TrustLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI